Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Zenas BioPharma has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Zenas BioPharma's investors include Norwest, Wellington Management, Perceptive Advisors, Vivo Capital, New Enterprise Associates.
Zenas BioPharma is headquartered in Waltham, United States.
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Zenas BioPharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Zenas BioPharma — Funding & Investors." VCBacked, March 27, 2026, https://www.vcbacked.co/company/zenas-biopharma. Accessed October 21, 2026.
VCBacked. (2026). Zenas BioPharma — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/zenas-biopharma
{{cite web |title=Zenas BioPharma — Funding & Investors |url=https://www.vcbacked.co/company/zenas-biopharma |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated